Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Biogen board slashes CEO’s bonus as Aduhelm sales and overall business struggle

  • Adam Feuerstein
  • Damian Garde

By Adam Feuerstein and Damian Garde April 29, 2022

Reprints
2020 Biogen
Steven Senn/AP

Biogen CEO Michel Vounatsos had his bonus cut in half to “hold him accountable for the company’s overall business performance in 2021,” according to a company filing Friday.

Al Sandrock, Biogen’s longtime chief scientist who was pushed out of the company amid a dispute with Vounatsos, did not receive a bonus in 2021, the same filing showed.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Authors Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Tags

Create a display name to comment

This name will appear with your comment

Wary of changes to Medicare Advantage, health insurers put…
Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the…
U.S. researcher says he’s ready to start four pregnancies…
U.S. researcher says he’s ready to start four pregnancies with ‘three-parent’ embryos
Oscar Health names former Aetna executive as new CEO
Oscar Health names former Aetna executive as new CEO
Pharmalittle: Ohio attorney general accuses PBMs of price fixing;…
Pharmalittle: Ohio attorney general accuses PBMs of price fixing; how cost-effectiveness fight could hobble drug price…
With new study data, Intra-Cellular could expand use of…
With new study data, Intra-Cellular could expand use of approved mood-disorder treatment
Viking Therapeutics releases early but promising weight loss data…
Viking Therapeutics releases early but promising weight loss data on new GLP-1 drug

Recommended Stories